Lipophilic drug delivery vehicle and methods of use thereof
View Patent ↗The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.
1. A bioactive agent delivery particle consisting essentially of at least one lipid binding polypeptide, a lipid bilayer, and one or more bioactive agents comprising at least one hydrophobic region wherein said bioactive agent is a non-polypeptide selected from the group consisting of antimicrobials, neurotransmitters, radiolabels, fluorescent compounds, antimetabolic agents, anesthetics, anticancer agents, anti-inflammatory agents, pesticides, insecticides, herbicides, all-trans retinoic acid, lipopolysaccharide, Vitamin E, and photosensitizing agents used in photodynamic therapy,
wherein the lipid bilayer comprises at least one phospholipid and the interior of the lipid bilayer comprises a hydrophobic region and the one or more bioactive agents is incorporated into the hydrophobic region of the lipid bilayer, and
wherein the particle
does not comprise an aqueous core,
is disc-shaped with the hydrophobic edge of the lipid bilayer circumscribed by the lipid binding polypeptide at the periphery of the particle and remains disc shaped in aqueous solution, and
wherein said lipid binding polypeptide comprises a class A amphipathic α-helix structural motif and/or a β-sheet motif and is selected from the group consisting of apolipoproteins and chimeric apolipoproteins.
2. A bioactive agent delivery particle according to claim 1 , wherein the disc shaped particle comprises a diameter from about 7 to about 29 nm.
3. A bioactive agent delivery particle according to claim 1 , wherein the bioactive agent is amphotericin B.
4. A bio active agent delivery particle according to claim 1 , wherein the bioactive agent is camptothecin.
5. A bioactive agent delivery particle according to claim 1 , wherein the lipid binding polypeptide is an apolipoprotein.
6. A bioactive agent delivery particle according to claim 5 , wherein the apolipoprotein is an exchangeable apolipoprotein.
7. A bioactive agent delivery particle according to claim 6 , wherein the apolipoprotein is human apolipoprotein A-I.
8. A bioactive agent delivery particle according to claim 1 , wherein the lipid binding polypeptide is a chimeric apolipoprotein that comprises a functional moiety.
9. A bioactive agent delivery particle according to claim 8 , wherein the functional moiety is a targeting moiety.
10. A bioactive agent delivery particle according to claim 8 , wherein the functional moiety comprises biological activity.
11. A bioactive agent delivery particle according to claim 5 , wherein the apolipoprotein has been modified to increase stability of the particle.
12. A bioactive agent delivery particle according to claim 11 , wherein the modification comprises introduction of cysteine residues to form intermolecular or intramolecular disulfide bonds.
13. A bioactive agent delivery particle according to claim 1 , wherein the phospholipids comprise dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
14. A pharmaceutical composition for delivery of a bioactive agent to an individual, comprising a bioactive agent delivery particle according to claim 1 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition according to claim 14 , wherein the composition is formulated for controlled release.
16. A method for administering a bioactive agent to an individual, comprising administering the pharmaceutical composition of claim 14 to the individual.
17. A method according to claim 16 , wherein said pharmaceutical composition comprises a therapeutically effective amount of the bioactive agent.
18. A method according to claim 17 , wherein the bioactive agent is amphotericin B.
19. A method according to claim 17 , wherein the bioactive agent is camptothecin.
20. A method according to claim 16 , wherein administration is parenteral.
21. A method according to claim 20 , wherein said parenteral administration is selected from the group consisting of intravenous, intramuscular, transmucosal, and intrathecal.
22. A method according to claim 16 , wherein the composition is administered as an aerosol.
23. A method according to claim 16 , wherein the composition is formulated for controlled release.
24. A kit comprising a pharmaceutical composition according to claim 14 and instructions for use in a method for administering a bioactive agent to an individual.
25. A bioactive agent delivery particle according to claim 1 , wherein the bioactive agent is an antimicrobial, a pesticide, or a herbicide.
26. A bioactive agent delivery particle according to claim 25 , wherein the antimicrobial is an antifungal.
27. A bioactive agent delivery particle according to claim 25 , wherein the bioactive agent is an insecticide.
28. A bioactive agent delivery particle according to claim 1 , wherein the bioactive agent is nystatin.
29. A bioactive agent delivery particle according to claim 1 , wherein the bioactive agent is an anticancer agent.
30. A bioactive agent delivery particle according to claim 1 , wherein the bioactive agent comprises all-trans retinoic acid, or Vitamin E.
31. A bioactive agent delivery particle according to claim 1 , wherein the lipid binding polypeptide is a peptide.
32. A bioactive agent delivery particle according to claim 31 , wherein the lipid binding polypeptide is an amphipathic peptide.
33. A bioactive agent delivery particle according to claim 5 , wherein the apolipoprotein is apolipoprotein E.
34. A bioactive agent delivery particle according to claim 33 , wherein the apolipoprotein is the N-terminal domain of apolipoprotein E.
35. A bioactive agent delivery particle according to claim 1 , wherein the phospholipids comprise dipalmitoylphosphatidylcholine (DPPC) or egg phosphatidylcholine.
36. A pharmaceutical composition, comprising a bioactive agent delivery particle according to claim 35 and a pharmaceutically acceptable carrier.
37. A composition for delivery of a bioactive agent to an individual, comprising a bioactive agent delivery particle of claim 1 and a carrier.
38. A composition according to claim 37 , wherein the individual is a plant or insect.
39. A composition according to claim 37 , wherein the bioactive agent is an antimicrobial, a pesticide, or a herbicide.
40. A composition according to claim 14 , wherein the composition is formulated for topical administration.
41. The method according to claim 16 , wherein administration is topical.
42. The method of claim 16 , wherein the individual is a plant.
43. The bioactive agent delivery particle according to claim 1 , wherein the apolipoprotein is selected from the group consisting of apolipoprotein A-I (ApoA-I), apolipoprotein E (ApoE), apolipoprotein E3 (ApoE3), apolipophorin III (ApoIII), apolipoprotein A-IV (ApoA-IV), apolipoprotein A-V (ApoA-V), apolipoprotein C-I (ApoC-I), apolipoprotein C-II (ApoC-II), apolipoprotein C-III (ApoC-III), apolipoprotein D (ApoD), apolipoprotein A-II (ApoA-II), apolipoprotein B-100 (ApoB-100), apolipoprotein J (ApoJ), apolipoprotein H (ApoH), and natural variants, analogs, fragments, isoforms, or chimeric forms thereof.
44. The bioactive agent delivery particle according to claim 1 , wherein the lipid binding polypeptide is an apolipoprotein natural variant, isoform, fragment or analog.
45. The bioactive agent delivery particle of claim 31 , wherein the peptide is a synthetic peptide.
46. The bioactive agent delivery particle according to claim 1 , wherein the apolipoprotein is the C-terminal or N-terminal domain of apolipoprotein E3 or isoform thereof.